Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab

Witzig, Thomas E.; Inwards, David J.; Habermann, Thomas M.; Dogan, Ahmet; Kurtin, Paul J.; Gross Jr, John B.; Ananthamurthy, Anuradha; Ristow, Kay M.; Garrity, James A.
June 2007
Mayo Clinic Proceedings;Jun2007, Vol. 82 Issue 6, p692
Academic Journal
OBJECTIVE: To report the results of treating patients with orbital pseudolymphomas with the anti-CD20 monoclonal antibody rituximab. PATIENTS AND METHODS: Patients were included in the study if they had an orbital mass and biopsy-proven orbital pseudolymphomas between January 1, 1998, and December 31, 2005. The study focused on patients treated with rituximab. RESULTS: Ninety-eight patients were evaluated, and the biopsy results revealed malignant non-Hodgkin lymphoma in 72 (73%); the other 26 (27%) had a pseudolymphoma. Eleven (42%) of the 26 patients with a pseudolymphoma were treated with rituximab, 375 mg/m², intravenously each week for 4 doses, and 10 (91%) of the 11 responded. Seven patients were either treated with maintenance rituximab or successfully retreated with rituximab after relapse. None of the 10 responders has become refractory to rituximab. CONCLUSION: Benign lymphoproliferative tumors are responsive to monoclonal antibody therapy targeted to B lymphocytes. Rituximab should be considered a treatment option for orbital pseudolymphomas.


Related Articles

  • Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjögren's Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma. Quartuccio, Luca; Fabris, Martina; Moretti, Massimo; Barone, Francesca; Bombardieri, Michele; Rupolo, Maurizio; Lombardi, Sandra; Pitzalis, Costantino; Beltrami, Carlo Alberto; Curcio, Francesco; de Vita, Salvatore // Open Rheumatology Journal;2008, Vol. 2, p38 

    Objective: B-cell expansion is a key feature of Sjögren's syndrome (SS). Accordingly, several studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and extraglandular manifestations of SS. Patients with SS are at...

  • Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Agustin Avilés; María Nambo; Natividad Neri; Sergio Cleto; Claudia Castañeda; Judith Huerta-Guzmàn; Edgar Murillo; Margarita Contreras; Alejandra Talavera; Martha González // Medical Oncology;Jan2007, Vol. 24 Issue 1, p85 

    Abstract  To assess efficacy and toxicity of rituximab and dose chemotherapy in high-risk diffuse large cell lymphoma, we conducted a controlled clinical trial to assess efficacy and toxicity of a dose-dense regimen CEOP-14 (cyclophosphamide, epirubicin, vincristine, and prednisone every...

  • Front-Line Treatment of Indolent Non-Hodgkin Lymphomas. Aurer, Igor // Current Medical Literature: Leukemia & Lymphoma;2007, Vol. 15 Issue 4, p93 

    The article discusses front-line treatment of indolent hon-Hodgkin lymphomas (NHL), neoplasma derived from peripheral lymphoid cells and characterized by prolonged clinical course. Rituximab is the only drug shown to significantly improve overall survival (OS) rates when used as part of a...

  • Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Lemieux, Bernard; Bouafia, Fadhela; Thieblemont, Catherine; Hequet, Olivier; Arnaud, Philippe; Tartas, Sophie; Traulle, Catherine; Salles, Gilles; Coiffier, Bertrand // Hematology Journal;2004, Vol. 5 Issue 6, p467 

    The purpose of this study was to evaluate retrospectively the effect of a second treatment with rituximab for patients who progressed after a response to a first treatment. We analysed the charts of 41 patients treated at CHU Lyon-Sud between 1997 and May 2003. Patients were treated with...

  • A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Arcaini, L; Orlandi, E; Alessandrino, Ep; Iacona, I; Brusamolino, E; Bonfichi, M; Bernasconi, P; Calatroni, S; Tenore, A; Montanari, F; Troletti, D; Pascutto, C; Regazzi, M; Lazzarino, M // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 2, p175 

    Summary:We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking...

  • Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Borgerding, Andrea; Hasenkamp, Justin; Glaß, Bertram; Wulf, Gerald; Trümper, Lorenz // Annals of Hematology;Mar2010, Vol. 89 Issue 3, p283 

    Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line...

  • Rituximab therapy in malignant lymphoma. Coiffier, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3603 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients....

  • ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’. Bonavida, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3629 

    Rituximab (chimeric anti-CD20 monoclonal antibody) is the first Food and Drug Administration approved antitumor antibody and is used in the treatment of B-non-Hodgkin's lymphoma (B-NHL). It is used as single monotherapy or in combination with chemotherapy and has improved the treatment outcome...

  • Rituximab.  // Reactions Weekly;Mar2014, Vol. 1493 Issue 1, p39 

    The article presents case studies of two patients who developed cytokine release syndrome and/or cardiovascular events following treatment with rituximab for lymphoma. One case is of a 75-year-old man who experienced a relapse of non-Hodgkin's small B-cell lymphoma. The second case is of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics